Pharmacological mechanism of mylabris in the treatment of leukemia based on bioinformatics and systematic pharmacology

References

• Preisler HD. The leukemias. Dis Mon. 1994;40(10):525–579.
   PubMed Web of Science ®Google Scholar
• Hsiao YL, Chang PC, Huang HJ, et al. Treatment of acute lymphoblastic leukemia from traditional chinese medicine. Evid Based Complement Alternat Med. 2014;2014:601064.
   PubMed Web of Science ®Google Scholar
• Li J, Li L, Liu R, et al. Establishing Chinese medicine characteristic tumor response evaluation system is the key to promote internationalization of Chinese medicine oncology. Chin J Integr Med. 2012;18(10):730–736.
   PubMed Web of Science ®Google Scholar
• Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998;339(19):1341–1348.
   PubMed Web of Science ®Google Scholar
• Miaofen X, Shuanglin Z. Pharmacological molecular mechanism of cantharidia based on bioinformatics and systematic pharmacology. Rep Trad Chin Med. 2019;25(20):60–65.
   Google Scholar
• Wang GS. Medical uses of mylabris in ancient China and recent studies. J Ethnopharmacol. 1989;26(2):147–162.
   PubMed Web of Science ®Google Scholar
• Chen RT, Hua Z, Yang JL, et al. Studies on antitumor actions of cantharidin. Chin Med J (Engl). 1980;93(3):183–187.
   PubMed Web of Science ®Google Scholar
• Wang G, Dong J, Deng L. Overview of cantharidin and its analogues. Curr Med Chem. 2018;25(17):2034–2044.
   PubMed Web of Science ®Google Scholar
• Dorn DC, Kou CA, Png KJ, et al. The effect of cantharidins on leukemic stem cells. Int J Cancer. 2009;124(9):2186–2199.
   PubMed Web of Science ®Google Scholar
• Wang SC, Chow JM, Chien MH, et al. Cantharidic acid induces apoptosis of human leukemic HL-60 cells via c-Jun N-terminal kinase-regulated caspase-8/-9/-3 activation pathway. Environ Toxicol. 2018;33(4):514–522.
   PubMed Web of Science ®Google Scholar
• Sun X, Cai X, Yang J, et al. Cantharidin overcomes imatinib resistance by depleting BCR-ABL in chronic myeloid leukemia. Mol Cells. 2016;39(12):869–876.
   PubMed Web of Science ®Google Scholar
• Naz F, Wu Y, Zhang N, et al. Anticancer attributes of cantharidin: involved molecular mechanisms and pathways. Molecules. 2020;25(14). DOI:10.3390/molecules25143279
   Web of Science ®Google Scholar
• Ru J, Li P, Wang J, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform. 2014;6:13.
   PubMed Web of Science ®Google Scholar
• Zhang Y-Q, Mao X, Guo Q-Y, et al. Network pharmacology-based approaches capture essence of chinese herbal medicines. Chinese Herbal Medicines. 2016;8(2):107–116.
   Web of Science ®Google Scholar
• von Mering C, Huynen M, Jaeggi D, et al. STRING: a database of predicted functional associations between proteins. Nucleic Acids Res. 2003;31(1):258–261.
   PubMed Web of Science ®Google Scholar
• Li L, Zhang N, Li S. Ranking effects of candidate drugs on biological process by integrating network analysis and gene ontology. Chinese Sci Bull. 2010;55(26):2974–2980.
   Google Scholar
• Ogata H, Goto S, Sato K, et al. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 1999;27(1):29–34.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Hough R. Leukemia. Prog Tumor Res. 2016;43:87–100.
   PubMed Web of Science ®Google Scholar
• Wang F, Lv H, Zhao B, et al. Iron and leukemia: new insights for future treatments. J Exp Clin Cancer Res. 2019;38(1):406.
   PubMed Web of Science ®Google Scholar
• Li LX, Tang YM, Zhang HZ, et al. Preparation of the immunotoxin 2E8-norcantharidin and its targeting killing effect in vitro. Zhonghua Er Ke Za Zhi. 2008;46(7):493–497.
   PubMedGoogle Scholar
• Ruirong X, Siyuan C, Yan W. Effect of cantharidin on hTERT mRNA expression and promoter methylation in leukemia HL60 cells. Shandong J Trad Chin Med. 2011;30(5):331–334.
   Google Scholar
• Yu Z, Li L, Wang C, et al. Cantharidin Induces apoptosis and promotes differentiation of AML cells through nuclear receptor Nur77-mediated signaling pathway. Front Pharmacol. 2020;11:1321.
   PubMed Web of Science ®Google Scholar
• Kim HN, Kim YK, Lee IK, et al. Association between polymorphisms of folate-metabolizing enzymes and hematological malignancies. Leuk Res. 2009;33(1):82–87.
   PubMed Web of Science ®Google Scholar
• Wiemels JL, Smith RN, Taylor GM, et al. Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia. Proc Natl Acad Sci U S A. 2001;98(7):4004–4009.
   PubMed Web of Science ®Google Scholar
• Aly RM, Taalab MM, Ghazy HF. MTHFR A1298C and C677T gene polymorphisms and susceptibility to chronic myeloid leukemia in Egypt. Int J Clin Exp Pathol. 2014;7(5):2571–2578.
   PubMed Web of Science ®Google Scholar
• Sinthuwiwat T, Poowasanpetch P, Wongngamrungroj A, et al. Association of MTHFR polymorphisms and chromosomal abnormalities in leukemia. Dis Markers. 2012;32(2):115–121.
   PubMed Web of Science ®Google Scholar
• Sazawal S, Chaubey R, Kaur P, et al. MTHFR gene polymorphisms and the risk of acute lymphoblastic leukemia in adults and children: a case control study in India. Indian J Hematol Blood Transfus. 2014;30(4):219–225.
   PubMed Web of Science ®Google Scholar
• Dorgham S, Aberkane M, Boughrara W, et al. Association between methylene-tetrahydrofolate reductase gene polymorphisms and chronic myeloid leukemia. Bull Cancer. 2014;101(9):803–807.
   PubMed Web of Science ®Google Scholar
• Lordelo GS, Miranda-Vilela AL, Akimoto AK, et al. Association between methylene tetrahydrofolate reductase and glutathione S-transferase M1 gene polymorphisms and chronic myeloid leukemia in a Brazilian population. Genet Mol Res. 2012;11(2):1013–1026.
   PubMed Web of Science ®Google Scholar
• Li C, Yichao J, Jiaxin L, et al. Methylenetetrahydrofolate reductase gene polymorphism and risk of chronic myelogenous leukemia: a meta-analysis. J buon. 2015;20(6):1534–1545.
   PubMed Web of Science ®Google Scholar
• Pant V, Quintás-Cardama A, Lozano G. The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans. Blood. 2012;120(26):5118–5127.
   PubMed Web of Science ®Google Scholar
• Barbosa K, Li S, Adams PD, et al. The role of TP53 in acute myeloid leukemia: challenges and opportunities. Genes Chromosomes Cancer. 2019;58(12):875–888.
   PubMed Web of Science ®Google Scholar
• Rauh R, Kahl S, Boechzelt H, et al. Molecular biology of cantharidin in cancer cells. Chin Med. 2007;2:8.
   PubMedGoogle Scholar
• Efferth T, Rauh R, Kahl S, et al. Molecular modes of action of cantharidin in tumor cells. Biochem Pharmacol. 2005;69(5):811–818.
   PubMed Web of Science ®Google Scholar
• Bonness K, Aragon IV, Rutland B, et al. Cantharidin-induced mitotic arrest is associated with the formation of aberrant mitotic spindles and lagging chromosomes resulting, in part, from the suppression of PP2Aalpha. Mol Cancer Ther. 2006;5(11):2727–2736.
   PubMed Web of Science ®Google Scholar
• Li DM, Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res. 1997;57(11):2124–2129.
   PubMed Web of Science ®Google Scholar
• Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275(5308):1943–1947.
   PubMed Web of Science ®Google Scholar
• Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997;16(1):64–67.
   PubMed Web of Science ®Google Scholar
• Downes CP, Ross S, Maccario H, et al. Stimulation of PI 3-kinase signaling via inhibition of the tumor suppressor phosphatase, PTEN. Adv Enzyme Regul. 2007;47:184–194.
   PubMedGoogle Scholar
• Chen CY, Chen J, He L, et al. PTEN: tumor suppressor and metabolic regulator. Front Endocrinol (Lausanne). 2018;9:338.
   PubMed Web of Science ®Google Scholar
• Freeman DJ, Li AG, Wei G, et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell. 2003;3(2):117–130.
   PubMed Web of Science ®Google Scholar